Owen Mumford

What Owen Mumford does

Owen Mumford is a privately held UK medical device manufacturer founded in 1952 in Oxfordshire by Ivan Owen and John Mumford, now operating as a wholly-owned subsidiary of Embecta Corp. following completion of Embecta's acquisition on 15 May 2026. The company designs and manufactures drug delivery devices and capillary blood sampling products, including the Aidaptus two-step single-use auto-injector platform (1 mL and 2.25 mL), the EcoSafe spring-free passive safety syringe with a companion reusable autoinjector (optional Bluetooth-enabled), Unifine SafeControl active safety pen needles, Unifine Pentips Plus all-in-one pen needles, and the Autolet lancing device and Unistik safety lancet range. Manufacturing is performed in GMP-compliant UK facilities (per EC Directive 93/42/EEC and 21 CFR Part 820), with a BREEAM "Very Good"-rated centre of excellence in Witney.

The business operates two intertwined revenue streams. The Pharmaceutical Services unit designs custom and platform devices for the world's leading pharmaceutical and diagnostic companies under Quality and Technical Agreements (Stevanato Group is the named Aidaptus co-development partner, Abbott is a license partner), combining OEM contract manufacturing with platform licensing and royalty income. The branded medical devices business sells Owen Mumford's own-brand products (Aidaptus, EcoSafe, Unifine, Autolet, Unistik, Autoject, Accupen) to healthcare professionals and patients in chronic care — principally diabetes — through direct B2B sales, the medicalshop.shop storefront, and regional distributors, with an exclusive UniSafe distribution agreement signed December 2024. Approximately 80% of revenue is generated in UK and US markets.

Reported FY2025 net revenue is approximately £69.4 million, down from £72.3M (FY ending September 2024) and £82.6M the prior year, while operating losses narrowed from ~£3.2M to ~£1.2M in FY2024. Following the Embecta acquisition, the company gains access to a global commercial infrastructure spanning diabetes, obesity, autoimmune disease, and anaphylaxis markets. Other recent additions include the March 2024 acquisition of Danish pelvic health brand Empelvic (Scandinavia entry) and the October 2025 EcoSafe platform expansion. The company holds B Corp certification (2021), is a UN Global Compact signatory, has committed to net zero by 2045 via the Science Based Targets initiative, and operates a registered patent portfolio across major jurisdictions including the US, EP, CN, JP, GB, KR and TW.

Name

Owen Mumford

Legal name

Owen Mumford Limited

Website

https://owenmumford.com

Company type

Private

Founded year

1952

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Owen Mumford is a UK medical device manufacturer (founded 1952, now part of Embecta Corp.) that designs and manufactures drug delivery devices — including the Aidaptus auto-injector and EcoSafe safety syringe platforms — and capillary blood sampling products for pharmaceutical companies, healthcare professionals, and chronic-care patients.

Ownership category

akta.pro rank

Product category

Drug Delivery Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Auto-Injectors (Disposable & Reusable) (HLAHAIAB)

akta.pro secondary industries

Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF)

Keywords

• Drug delivery devices
• Auto-injector platforms
• Safety pen needles
• Capillary blood sampling
• Medical device manufacturing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Branded medical device sales: Sales of proprietary branded medical devices (Aidaptus, EcoSafe, Unifine SafeControl, Unifine Pentips Plus, Autolet, Unistik, Autoject) under Owen Mumford's own brand to global customers.
2. Custom device development and contract manufacturing: B2B contracts with major pharmaceutical and diagnostic companies to design, develop, and manufacture custom drug delivery devices under Quality and Technical Agreements; governed by GMP.
3. Licensed patent and IP royalties: Licensing of patented technology (e.g., Abbott SF) and IP rights to third parties for use in their products.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Owen Mumford designs and manufactures medical devices for drug delivery and capillary blood sampling, including auto-injectors (Aidaptus), safety pen needles (Unifine SafeControl, Unifine Pentips Plus), spring-free passive safety syringes (EcoSafe 1 mL and 2.25 mL) with a companion reusable autoinjector, and lancing devices and safety lancets (Autolet, Unistik, Unilet). The company sells under proprietary brands and provides custom device design, development and GMP-compliant contract manufacturing services for the world's leading pharmaceutical and diagnostic companies.

Differentiator

Problem solved

Functional benefit

Brands

• Autolet: World's first automatic lancing device for blood glucose monitoring (Autolet Plus)
• Accupen
• Autoject
• Unifine Pentips Plus
• Unifine SafeControl
• EcoSafe
• Aidaptus
• Unistik
• Unilet

Products and services

• Aidaptus auto-injector A two-step, single-use, disposable auto-injector platform designed to accommodate both 1 mL and 2.25 mL prefilled glass syringes within the same base device, aimed at pharmaceutical and biotech partners for subcutaneous self-administration of biologics and other injectables.
• EcoSafe 1 mL safety syringe A spring-free passive safety syringe engineered to reduce the risk of needlestick injury after injection of 1 mL prefilled syringes, designed as a platform component that can be paired with the EcoSafe reusable autoinjector; eco-friendly design with 5g disposable weight, full syringe barrel visibility and three-year shelf life.
• EcoSafe 2.25 mL safety syringe A larger-volume variant of the EcoSafe spring-free passive safety syringe platform, supporting 2.25 mL prefilled syringes to enable a broader range of dose volumes within the same EcoSafe ecosystem.
• EcoSafe reusable autoinjector A companion reusable auto-injector for the EcoSafe 1 mL safety syringe, rated for up to 100 injections, fully recyclable, and offered with an optional Bluetooth-enabled variant that automatically transfers injection data to healthcare providers; offers lifetime battery of up to four years total battery life and stores over 1,000 injection records.
• Unifine SafeControl An active safety pen needle for insulin and other pen-injector therapies, combining an integrated removal chamber with a manually activated safety mechanism to reduce the risk of needlestick injury after injection; available in 4mm 32G, 5mm 30G and 8mm 30G with dual visual and audible safety indicators and a green sterility cap.
• Unifine Pentips Plus A universal pen needle featuring an integrated needle-removal chamber and Safe Click Technology that audibly indicates when used needles are disposed into the locking chamber, enabling users to remove and safely store used needles after injection without needing a separate sharps container.
• Autolet Plus lancing device An automatic lancing device used with capillary-action lancets (e.g., Unilet, Unistik) to obtain a capillary blood sample for self-monitoring of blood glucose and other point-of-care testing; recognised as the world's first automatic lancing device.
• Unistik 3 safety lancets A safety lancet range for capillary blood collection offered in Gentle, Comfort, Normal, Extra and Neonatal variants, designed to provide controlled, single-use capillary sampling with reduced needlestick injury risk.
• Pharmaceutical Services custom device design and contract manufacturing Custom end-to-end device design, development and GMP-compliant contract manufacturing services for the world's leading pharmaceutical and diagnostic companies, embedding Owen Mumford's drug delivery platforms (Aidaptus, EcoSafe, Unifine) into combination products under Quality and Technical Agreements.

Quantifiable outcome

• £69.4 million in net revenue during fiscal year 2025, with about 80% derived from UK and US markets
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered minor (transaction-specific), flagship / transformational, minor (sustainability), minor (regional), core and minor (sustainability positioning).

• Forvis Mazarsminor (transaction-specific)Implementation/ SI/ Consulting Partner · 18 May 2026Forvis Mazars advised on the sale of Owen Mumford to Embecta for up to £150m; managed the sale process including marketing, due diligence, and negotiations of the £100m upfront cash + up to £50m performance-based component tied to Aidaptus auto-injector net sales.
• Embecta Corpflagship / transformationalStrategic or Co-development Partner · 15 May 2026Embecta Corp (Nasdaq: EMBC) completed the acquisition of Owen Mumford Holdings Limited on May 15, 2026 for an upfront cash payment of £100 million plus up to £50 million in performance-based payments tied to Aidaptus auto-injector net sales through June 2029. The transaction accelerates Embecta's strategic transformation into a broader medical supplies company serving chronic care patients across obesity, diabetes, autoimmune diseases, and anaphylaxis markets, combining Owen Mumford's device design and manufacturing capabilities with Embecta's global commercial infrastructure.
• Eden Reforestation Projectsminor (sustainability)Others · 1 January 2025Partnership with Eden Reforestation Projects resulted in the planting of 468 trees in response to the number of completed engagement survey submissions. Each tree planted reduces carbon and provides employment for impoverished people in these areas.
• Exclusive UniSafe distribution partnerminor (regional)Channel Partner/ Reseller/ Distributor · 1 December 2024Exclusive distribution agreement signed in December 2024 for the UniSafe product (note: EcoSafe was initially launched as UniSafe). Specific distribution partner not named in source material.
• EmpelviccoreStrategic or Co-development Partner · 26 March 2024Owen Mumford acquired Danish pelvic health brand Empelvic to expand its offerings in intimate health solutions and to expand Empelvic's reach across Scandinavia. The acquisition enhances Owen Mumford's portfolio beyond drug delivery devices into pelvic health consumer products.
• Stevanato GroupcoreStrategic or Co-development Partner · 1 October 2022Collaborated with Stevanato Group to produce the Aidaptus auto-injector platform. Drug Development & Delivery interviewed Michael Earl (Director of Pharmaceutical Services, Owen Mumford) and Steven Kaufman (VP for Drug Delivery Systems, Stevanato Group) on the collaboration. Owen Mumford's pharmaceutical services and Stevanato's glass primary container technology combine to deliver the platform to pharma customers.
• UN Global Compact Network UKminor (sustainability positioning)GTM or Marketing Partner · 1 January 2020Owen Mumford sponsors a series of UN Global Compact Network UK webinars focusing on reducing scope 3 emissions, helping businesses credibly measure, report and reduce these emissions. As a member, Owen Mumford supports the events while educating itself throughout the series.
• AbbottcoreOEM/ Whitelabel/ Licensing Partner · 1 December 2017Abbott SF product is covered by licensed patent US7,972,349B2 — Owen Mumford holds or licenses this patent for the Abbott SF product line, indicating a technology licensing arrangement covering this safety lancet/lancing device family.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ypsomed Holding AG: Swiss-headquartered manufacturer of pen needles, autoinjectors and patch injectors serving the same pharmaceutical/biotech combination-product customers (insulin, GLP-1, biologics). Closely comparable in product mix (pen needles + auto-injectors), B2B pharma-services go-to-market, and Swiss/UK manufacturing footprint.
• SHL Medical: Private global leader in autoinjector design and manufacturing, with Molly, DAI, and Rapidus platforms serving the same large pharma combination-product customers. Direct competitor to Aidaptus in the single-use auto-injector segment.
• West Pharmaceutical Services: US-listed provider of primary container closures, drug delivery components (including SmartDose and proprietary elastomer/plunger systems), and contract manufacturing for injectable combination products. Overlaps directly with Owen Mumford's Pharmaceutical Services platform-device offering.
• Stevanato Group: Italy-based drug containment and delivery solutions provider (glass syringes, vials, drug delivery devices) and explicit Aidaptus co-development partner with Owen Mumford. Closely aligned product portfolio and shared pharma customer base.
• Gerresheimer AG: German-headquartered manufacturer of pharmaceutical glass, plastic primary packaging, syringes, pens and auto-injectors serving pharma/biotech customers globally. Direct competitor in prefilled syringes and combination-product delivery devices.
• AptarGroup: US-listed provider of drug delivery systems including auto-injectors, nasal spray pumps, prefilled syringe components and connected device platforms serving pharmaceutical customers. Comparable B2B pharma combination-product model.

Broad incumbents

• Becton, Dickinson and Company (BD): Global medical device incumbent with a large Pharmaceutical Systems segment producing prefillable syringes, safety syringes, pen needles, and autoinjectors. Overlaps with Owen Mumford across most product lines but as part of a much broader medtech portfolio.
• Terumo Corporation: Japanese-headquartered medical device manufacturer with a significant injection/drug-delivery business (Terumo Syringe, PLAJEX prefillable syringes, pen needles). Competes in the same prefilled syringe and pen needle categories but is a much larger diversified medtech player.
• B. Braun SE: German-headquartered medical technology and pharmaceutical solutions company producing injection systems, infusion therapy, and pen needles (including Omnican and Injekt brands). Comparable offerings in pen needles and safety injection devices as part of a wider hospital and pharma products portfolio.
• Nipro Corporation: Japanese-headquartered medical device and pharmaceutical glass manufacturer producing prefilled syringes, pen needles (Nipro P.I. needles), and injection devices for diabetes care. Overlaps with Owen Mumford's pen needle and safety syringe lines through a broader medtech portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/owen-mumford-ltd
• Facebookfacebook.com/owenmumford
• YouTubeyoutube.com/owenmumford
• Xx.com/owenmumford

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Owen Mumford